Lv4
792 积分 2020-08-09 加入
A First-in-Human, Phase 1, Multicenter, Open-label, Dose-Escalation Study of PCA062, an Antibody-Drug Conjugate Targeting P-Cadherin, in Patients with Solid Tumors
9天前
已完结
PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
9天前
已完结
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
9天前
已完结
Nectin-4 Expression Patterns and Therapeutics in Oncology
17天前
已完结
TOP-1 Priority: Advancing Biomarker-Driven Patient Selection for the use of ADCs
18天前
已完结
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
18天前
已完结
Non-small-cell lung cancer
21天前
已完结
Trends in the drug target landscape for autoimmune diseases
25天前
已完结
Treatment of advanced or metastatic Urothelial Cancer
29天前
已关闭
Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents
1个月前
已完结
皖公网安备34019202002308
